Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 18/20 | 0.53 |
| ▸ | CASP6 | P55212 | 17/20 | 0.53 |
| ▸ | CASP8 | Q14790 | 17/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473171 | 1.00 | CASP1 (0.54) | CASP1CASP3CASP6CASP8CASP7 | |
| SCHEMBL473172 | 1.00 | CASP1 (0.54) | CASP1CASP3CASP6CASP8CASP7 | |
| SCHEMBL2001699 | 0.92 | CASP1 (0.56) | CASP1CASP3CASP6CASP8CASP7 | |
| SCHEMBL2001700 | 0.92 | CASP1 (0.56) | CASP1CASP3CASP6CASP8CASP7 | |
| SCHEMBL6005322 | 0.90 | CASP1 (0.54) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL473276 | 0.90 | CASP1 (0.54) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL473217 | 0.90 | CASP1 (0.55) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL473275 | 0.90 | CASP1 (0.54) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL473214 | 0.90 | CASP1 (0.55) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL473274 | 0.90 | CASP1 (0.54) | CASP1CASP3CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412707-A2 | 3-[2-(3-Amino-2-oxo-2H-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7960415-B2 | Caspase inhibitors and uses thereof | Vertex Pharmaceutical Incoporated (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090093416-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-09 | — | — | US | disclosed |
| US-20040242494-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242494-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP3 | CASP1 1/4885CASP3 3/4885CASP6 8/4885 |
| US-20090093416-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP5, CASP3 | CASP1 1/4885CASP3 3/4885CASP6 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.